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Purpose
The purpose of this study was to evaluate the benefits of adjuvant treatment for curatively
resected thoracic esophageal squamous cell carcinoma (ESCC) and determine the optimal
adjuvant treatments. 
Materials and Methods
One hundred ninety-five patients who underwent a curative resection for thoracic ESCC 
between 1994 and 2014 were reviewed retrospectively. Postoperatively, the patients 
received no adjuvant treatment (no-adjuvant group, n=68), adjuvant chemotherapy (AC
group, n=62), radiotherapy (RT group, n=41), or chemoradiotherapy (CRT group, n=24).
Chemotherapy comprised cisplatin and 5-fluorouracil administration every 3 weeks. The
median RT dose was 45.0 Gy (range, 34.8 to 59.4 Gy). The overall survival (OS), disease-
free survival (DFS), locoregional recurrence (LRR), and distant metastasis (DM) rates were
estimated. 
Results
At a median follow-up duration of 42.2 months (range, 6.3 to 215.2 months), the 5-year OS
and DFS were 37.6% and 31.4%, respectively. After adjusting for other clinicopathologic
variables, the AC and CRT groups had a significantly better OS and DFS compared to the
no-adjuvant group (p < 0.05). The LRR rate was significantly lower in the RT and CRT groups
than in the no-adjuvant group (p < 0.05), whereas no significant difference was observed
in the AC group. In the no-adjuvant and AC groups, 25% of patients received high-dose sal-
vage RT due to LRR. The DM rates were similar. The anastomotic stenosis and leakage
were similar in the treatment groups. 
Conclusion
Adjuvant treatment might prolong survival after an ESCC resection, and RT contributes to a
reduction of the LRR. Overall, the risks and benefits should be weighed properly when 
selecting the optimal adjuvant treatment.
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Introduction
Esophageal cancer is a fatal disease that causes 400,000
deaths per year worldwide [1]. The current guidelines rec-
ommend surgery as the mainstay of treatment for esophageal
cancer [2,3]. Although neoadjuvant chemoradiotherapy
(CRT) is the treatment of choice for locally advanced
esophageal cancer [4], upfront surgery has been performed
for several decades. Currently, some patients continue to 
undergo upfront surgery for a variety of reasons. On the
other hand, radical esophagectomy without adjuvant treat-
ment has been associated with suboptimal disease control
rates [5]. A few randomized trials have been conducted to
evaluate the benefits of adjuvant chemotherapy (AC) and
postoperative radiotherapy (RT) [6,7]. Although these trials
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failed to demonstrate a survival benefit of adjuvant treat-
ment, these treatments reduced the recurrence rates signifi-
cantly. In addition, certain subgroups of patients, such as
node-positive patients, who received adjuvant treatment
showed significantly higher survival rates  [8,9]. Recently,
some researchers suggested that a combination of chemo-
therapy and RT might reduce the recurrence rate and 
improve survival [10]. 
Unfortunately, there is no clear consensus regarding
whether adjuvant treatment is required after a complete 
resection and what this ideal adjuvant treatment might be.
At the authors’ institution, the practice has changed from 
upfront surgery to neoadjuvant treatment followed by sur-
gery in response to the accumulating evidence supporting
the benefits of neoadjuvant treatment. On the other hand,
some patients without adjacent organ invasion or equivocal
lymph node involvement undergo upfront surgery, either
with or without adjuvant treatment. Patients with an
esophageal squamous cell carcinoma (ESCC) who under-
went upfront surgery were reviewed retrospectively to 
determine the effects of adjuvant treatment and the optimal
adjuvant treatment.
Materials and Methods
1. Patients 
This study identified 330 patients who underwent a front-
line radical resection for nonmetastatic thoracic ESCC 
between April 1994 and October 2014. None of the patients
had received preoperative RT or chemotherapy. Patients
with pathological stage T1N0 (n=102), a history of other can-
cer (n=19), and/or death within 2 months postoperatively
(n=14) were excluded, yielding a total of 195 patients for
analysis. 
The preoperative evaluation included a physical examina-
tion, laboratory blood tests, esophagogastroduodenoscopy
with biopsy, endoscopic ultrasonography, chest computed
tomography (CT), abdominopelvic CT, and positron emis-
sion tomography scanning. 
2. Surgery
Details of the surgical resection are described elsewhere
[11,12]. Briefly, patients with middle and lower esophageal
cancers underwent a transthoracic esophagectomy with a
two-field lymph node dissection and cervical esophagogas-
trostomy, using the whole stomach as a conduit (McKeown
esophagectomy). Gastric pull-up was performed through the
substernal route. A three-field lymph node dissection was
performed on the patients with upper esophageal cancer. 
Beginning in 2006, a robot-assisted thoracoscopic esophagec-
tomy protocol was adopted and the results have been 
reported [13]. Pathology staging was determined according
to the seventh edition of the American Joint Committee on
Cancer staging system. 
3. Adjuvant treatment
Adjuvant treatment was administered 4-6 weeks after sur-
gery in accordance with the pathology risk factors, physi-
cians’ preference, patients’ performance status, and age. In
general, the indications for adjuvant RT included a positive
resection margin, locally advanced disease (T3-4), and mul-
tiple positive lymph nodes. AC was administered commonly
to node-positive patients. Sixty-eight patients received no 
adjuvant treatment (no-adjuvant group); 62 patients received
AC without RT (AC group); 41 patients received RT without
chemotherapy (RT group); and 24 patients received both RT
and AC (CRT group).
The median RT dose was 45 Gy (range, 34.8 to 59.4 Gy),
which was delivered in daily fraction doses of 1.8 Gy. One
patient did not complete the planned treatment of 45 Gy and
refused further treatment after receiving 34.8 Gy. The RT
field included the tumor bed, anastomosis site, and lymph
node drainage areas. Although the supraclavicular fossa was
not irradiated routinely, it was performed on the patients
with upper esophageal cancer or involvement of the supra-
clavicular lymph nodes. 
The chemotherapy regimen comprised the intravenous 
infusion of cisplatin and 5-fluorouracil every 3 weeks for 
4-6 cycles. For the patients in the CRT group, RT was initi-
ated 1 week after the completion of two cycles of chemother-
apy in a sequential manner. Chemotherapy was re-initiated
after the completion of RT. 
4. Follow-up evaluation
The patients were followed up every 3 months after the
esophagectomy for the first year, every 6 months for the next
2 years, and annually thereafter. Abdominopelvic CT was
performed every 6-12 months and an esophagogastroduo-
denoscopy was performed annually. The incidence of post-
operative complications, such as anastomotic stenosis and
leakage, were evaluated. Endoscopic balloon dilatation was
performed when symptomatic anastomotic stenosis was 
evident and prevented the passage of the gastroduodeno-
scope. A biopsy was performed if a malignant anastomotic
stricture was suspected. 
Recurrences at the anastomotic site, tumor bed, and 
regional lymph node area were considered locoregional,
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Table 1. Characteristics of the patients in the four treatment groups
Characteristic No-adjuvant AC RT CRT p-value(n=68) (n=62) (n=41) (n=24)
Age (yr)
 60 20 (29.4) 32 (51.6) 22 (53.7) 15 (62.5) 0.008
> 60 48 (70.6) 30 (48.4) 19 (46.3) 9 (37.5)
Sex
Male 58 (85.3) 57 (91.9) 40 (97.6) 21 (87.5) 0.166a)
Female 10 (14.7) 5 (8.1) 1 (2.4) 3 (12.5)
ECOG performance status
0 52 (76.5) 56 (90.3) 26 (63.4) 17 (70.8) 0.117
1 16 (23.5) 6 (19.7) 15 (36.6) 7 (29.2)
Location
Upper to mid thoracic 32 (47.1) 21 (33.9) 17 (41.5) 7 (29.2) 0.310
Lower thoracic to EGJ 36 (52.9) 41 (66.1) 24 (58.5) 17 (70.8)
Histologic grade
Grade 1 or unknown 9 (13.2) 14 (22.6) 12 (29.3) 3 (12.5) 0.150
Grade 2-3 59 (86.8) 48 (77.4) 29 (70.7) 21 (87.5)
Tumor length (cm)
 5 58 (85.3) 47 (75.8) 29 (70.7) 17 (70.8) 0.246
> 5 10 (14.7) 15 (24.2) 12 (29.3) 7 (29.2)
T classification
T1 13 (19.1) 16 (25.8) 1 (2.4) 7 (29.2) 0.003a)
T2 28 (41.2) 14 (22.6) 9 (22.0) 5 (20.8)
T3 26 (38.2) 32 (51.6) 31 (75.6) 12 (50.0)
T4 1 (1.5) 0 ( 0 ( 0 (
N classification
N0 34 (50.0) 7 (11.3) 17 (41.5) 3 (12.5) < 0.001a)
N1 24 (35.3) 31 (50.0) 16 (39.0) 15 (62.5)
N2 8 (11.8) 17 (27.4) 6 (14.6) 5 (20.8)
N3 2 (2.9) 7 (11.3) 2 (4.9) 1 (4.2)
Lymphovascular invasion
No 56 (82.4) 43 (69.4) 33 (80.5) 15 (62.5) 0.126
Yes 12 (17.6) 19 (30.6) 8 (19.5) 9 (37.5)
Perineural invasion
No 64 (94.1) 55 (88.7) 37 (90.2) 23 (95.8) 0.618a)
Yes 4 (5.9) 7 (11.3) 4 (9.8) 1 (4.2)
Resection margin
R0 66 (97.1) 58 (93.5) 38 (92.7) 24 (100) 0.506a)
R1 2 (2.9) 4 (6.5) 3 (7.3) 0
Extracapsular extension
No 61 (89.7) 46 (74.2) 30 (73.2) 20 (83.3) 0.080
Yes 7 (10.3) 16 (25.8) 11 (26.8) 4 (16.7)
Treated period
1994 to 2002 32 (47.1) 26 (41.9) 30 (73.2) 11 (45.8) 0.013
2003 to 2014 36 (52.9) 36 (58.1) 11 (26.8) 13 (54.2)
AC, adjuvant chemotherapy; RT, radiotherapy; CRT, chemoradiotherapy; ECOG, Eastern Cooperative Oncology Group; EGJ,
esophagogastric junction. a)Fisher exact test. 
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Fig. 1. Estimated overall survival (OS) (A), disease-free survival (DFS) (B), locoregional recurrence (LRR) (C), and distant
metastasis (DM) rates (D) of the patients who received no adjuvant treatment, adjuvant chemotherapy (AC), postoperative
radiotherapy (RT), and postoperative chemoradiotherapy (CRT). CI, confidence interval.
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whereas recurrences elsewhere were considered distant. 
5. Statistical analysis 
A Pearson’s chi-square test or Fisher exact test was per-
formed where appropriate to compare the characteristics of
the different patient groups. The overall survival (OS), dis-
ease-free survival (DFS), locoregional recurrence (LRR), and
distant metastasis (DM) rates were calculated from the date
of surgery to the date of death from any cause, any recur-
rence or death, LRR, and distant metastasis, respectively. The
survival endpoints were analyzed using the Kaplan-Meier
method with a log-rank test for comparisons of the three
treatment groups. The LRR and DM rates were estimated
using the cumulative incidence method and Gray’s test [14].
To adjust for the effects of other variables on the treatment
outcome of the different adjuvant treatments, multivariable
models were generated to include the factors with p-values
of < 0.10 in univariate analyses. Cox proportional hazards 
regression was used to conduct univariate and multivariate
analyses of the OS and DFS. For LRR and DM, univariate and
multivariate models were generated by Fine and Gray 
regression analysis [15]. All tests were two-sided and con-
sidered significant at a p-value < 0.05. Statistical analyses
were performed using IBM SPSS ver. 20.0 (IBM Corp., 
Armonk, NY) and R software ver. 3.2.2 (R Development Core
Team, Vienna, Austria).
Results
1. Patient and treatment characteristics
Table 1 lists the characteristics of the patients in the no-
adjuvant, AC, RT, and CRT groups. The no-adjuvant group 
included a larger number of elderly patients, whereas the
AC, RT, and CRT groups included more locally advanced
patients. The majority of patients who received adjuvant
treatment had lymph node involvement and adventitial 
invasion. Fewer patients were treated with RT alone in the
more recent period. The tumor location, histology grade,
tumor length, and other histologic risk factors were similar
in the three groups. Most patients underwent a McKeown
esophagectomy (n=159), whereas others underwent an Ivor-
Lewis (n=21) or transhiatal esophagectomy (n=15). 
A median of four cycles (range, 1 to 6) of chemotherapy
were administered. Nine patients (eight in the AC group and
one in the CRT group) did not complete the planned
chemotherapy due to poor performance (n=6) and refusal
(n=3). One patient failed to complete the full course of RT,
and 22 patients had a treatment break during RT. 
2. Survival rates according to different adjuvant treatments
The median follow-up duration was 42.2 months (range,
6.3 to 215.2 months). The median OS and DFS durations were
36.0 months (95% confidence interval [CI], 27.5 to 44.5) and
23.7 months (95% CI, 16.5 to 30.9), respectively. The 5-year
OS and DFS rates were 37.6% (95% CI, 30.7 to 46.0) and 31.4%
(95% CI, 24.9 to 39.5), respectively. The OS and DFS were
similar in the different treatment groups (Fig. 1A and B). In
particular, sex, T classification, N classification, lymphovas-
cular invasion, resection margin, and treated period were sig-
nificant factors associated with both DFS and OS (Table 2).
After adjusting for these significant clinicopathological fac-
tors, the AC (adjusted hazard ratio [aHR], 0.47; 95% CI, 0.28
to 0.77) and CRT groups (aHR, 0.52; 95% CI, 0.29 to 0.96) 
exhibited a significantly lower risk of death relative to the
no-adjuvant group. In addition, the AC (aHR, 0.56; 95% CI,
0.35 to 0.90), RT (aHR, 0.58; 95% CI, 0.35 to 0.98), and CRT
groups (aHR, 0.51; 95% CI, 0.28 to 0.91) exhibited a signifi-
cantly lower risk of recurrence or death compared to the 
no-adjuvant group.
3. Patterns of initial recurrence and recurrence rates
Table 3 provided the data concerning recurrences. LRR
was the dominant pattern of recurrence in the no-adjuvant
group, whereas DM was dominant in the RT and CRT
groups. The rates of LRR and DM were similar in the AC
group. The 5-year LRR rate was lowest in the CRT group
(Fig. 1C). Compared to the no-adjuvant group, the RT and
CRT groups had a significantly lower risk of LRR, whereas
the AC group did not. After adjusting for the significant fac-
tors, the RT (aHR, 0.26; 95% CI, 0.13 to 0.54) and CRT groups
(aHR, 0.05; 95% CI, 0.01 to 0.39) exhibited a significantly
lower risk of LRR (Table 4). The 5-year DM incidence was
similar in the treatment groups (p=0.186) (Fig. 1D), even after
the adjustment (Table 4).
4. Application of RT after LRR
A total of 52 patients who did not receive postoperative RT
experienced LRR. Among these patients, 40 underwent sal-
vage treatment for the recurrent lesions; locoregional RT was
delivered to 33 patients, including 18 in the no-adjuvant
group and 15 in the AC group. A median dose of 59.4 Gy
(range, 14.4 to 63.0 Gy) was delivered to these patients. After
salvage RT, 18 patients exhibited a partial response or stable
disease, nine progressed, and six were nonevaluable accord-
ing to the Response Evaluation Criteria in Solid Tumors ver.
1.1 [16]. The median survival duration after salvage RT was
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10.1 months and was 15.2 months for those who did not
progress after salvage RT.
5. Postoperative complications 
The overall incidence of anastomotic stenosis requiring 
intervention (e.g., endoscopic balloon dilatation) was 29.2%,
and was similar in the no-adjuvant, AC, RT, and CRT groups
(29.4% vs. 30.6% vs. 26.8% vs. 29.2%, p=0.991). Anastomotic
leakage was an uncommon event with an overall incidence
of 3.6%; no significant differences were observed among the
no-adjuvant, AC, RT, and CRT groups (1.5% vs. 4.8% vs.
4.9% vs. 4.2%, p=0.651). None of the patients who received
RT suffered from severe radiation-induced gastritis. 
Discussion
In the present study, patients with resected ESCC who 
received AC and postoperative CRT showed significantly
higher survival rates than those who did not receive adjuvant
treatment. In terms of LRR, those who received adjuvant
treatments that included RT experienced significantly less
LRRs than those who did not receive adjuvant treatment.
Currently, patients with locally advanced ESCC are treated
preferably with preoperative CRT followed by a resection,
rather than upfront surgery [4]. On the other hand, a certain
portion of patients may undergo upfront surgery because of
the patients’ or physicians’ preferences, an inability to receive
preoperative chemotherapy or RT, and/or minimally 
advanced-stage disease. In such cases, the current guidelines
do not suggest further treatment after a R0 resection for
ESCC because of a lack of randomized evidence of improved
survival after adjuvant treatment [2,3]. 
Several randomized trials that compared surgery with or
without postoperative RT demonstrated a lack of a survival
benefit [7,17-19]. The most recently conducted randomized
trial, however, showed that stage III patients gained a signif-
icant survival benefit from postoperative RT [7]. In Japan, a
randomized controlled trial that compared surgery with and
without AC failed to show a significant OS benefit [6]. In con-
trast, several retrospective studies have shown higher sur-
vival rates in patients with positive lymph nodes or stage III
disease who received postoperative RT or AC compared to
the no-adjuvant treatment [8,20-23]. Similarly, in the present
study, the AC and CRT group showed a significantly lower
risk of death compared to the no-adjuvant group even after
adjusting for other clinicopathologic variables. Most patients
in this study had either lymph node involvement or local 
invasion beyond the muscularis propria. For patients with
less advanced disease after a resection, adjuvant treatment
might not yield a demonstrably significant survival benefit. 
No randomized controlled trials have been conducted to
compare the treatment outcomes of different adjuvant treat-
ments. Chen et al. [24] reviewed retrospectively 366 patients
with mid-thoracic ESCC who underwent an esophagectomy
followed by no-adjuvant treatment, AC, or RT. Although
they did not compare the survival, they found that patients
who received RT had a significantly lower incidence of 
regional recurrence. On the other hand, a remaining concern
regarding postoperative RT is that it cannot prevent recur-
rences beyond the radiation field; therefore, distant metas-
tases comprise the major failure sites [21]. Despite the limited
data, a recent report on patients with node-positive ESCC
showed that patients receiving both chemotherapy and post-
operative RT had lower recurrences rates, including distant
metastases, and superior OS compared to those receiving
postoperative RT only [10]. According to the data in the pres-
ent study, the CRT group, not the RT group, showed signif-
icantly higher OS than the no-adjuvant group. In addition,
the LRR risk reduction rate was more prominent in the CRT
group than in the RT group. No difference in DM was 
observed with the addition of chemotherapy. The most plau-
sible explanation for these findings appears to be an imbal-
Table 3. Patterns of initial recurrence
Event No-adjuvant AC RT CRT(n=68) (n=62) (n=41) (n=24)
Locoregional recurrence 28 (41.2) 24 (35.3) 10 (24.4) 1 (4.2)
Local only 6 (8.8) 2 (2.9) 2 (4.9) 0 (
Regional only 19 (27.9) 17 (25.0) 8 (19.5) 1 (4.2)
Local and regional 3 (4.4) 5 (7.4) 0 ( 0 (
Distant recurrence 14 (20.6) 22 (35.5) 13 (31.7) 9 (37.5)
Concurrent locoregional and distant recurrence 8 (11.8) 11 (16.2) 2 (4.9) 0 (
Values are presented as number (%). AC, adjuvant chemotherapy; RT, radiotherapy; CRT, chemoradiotherapy.
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ance in the tumor characteristics among the different treat-
ment groups. Patients who received chemotherapy were
more likely to have the risk factors for distant metastasis,
such as lymph node involvement and lymphovascular inva-
sion compared to those who did not receive AC. 
When deciding the optimal adjuvant treatment, the risks
and benefits of the treatment should be measured. This study
suggests that both AC and CRT might effectively increase
the OS; therefore, AC would be a better option because RT
could be spared. On the other hand, 25% (33 of 130) of the
patients who did not receive postoperative RT ultimately 
received locoregional RT because of LRR; these patients com-
prised 63% (33 of 52) of those who developed a LRR. A 
median dose of 60 Gy was delivered to these recurrent 
patients, which is considered a definitive dose for gross
tumor eradication. This suggests that 75% of patients could
have been spared unnecessary RT. More than half of the 
patients responded to salvage RT, leading to a median sur-
vival of 15 months after recurrence. A previous phase II trial
reported a median survival of 35 months after salvage CRT
[25]. These salvage rates, however, were consequent to high-
dose irradiation to the mediastinum. In particular, the dose
delivered in a recurrent setting is higher than that adminis-
tered to patients receiving postoperative RT (45-50 Gy). In
patients subjected to thoracic surgery, the actual effects of RT
on the surrounding normal organs might be more prominent
than the anticipated effects (based on nonoperated patients),
and a higher dose might cause fatal damage to the surround-
ing organs. Therefore, patients at a higher risk of LRR might
benefit most from RT because it could reduce the need for
subsequent high-dose RT. 
One of the greatest concerns associated with postoperative
RT after esophagectomy is the risk of anastomotic leakage
and stenosis. A randomized trial reported an increased inci-
dence of anastomotic stenosis after postoperative RT [17]. In
contrast, a more recent randomized trial observed no signif-
icant increase in the incidence of anastomotic stenosis after
postoperative RT [7]. These results also support the finding
that postoperative RT does not increase significantly the 
incidence of anastomotic stenosis or leakage after esophagec-
tomy. In addition, severe gastritis was not observed after RT,
mainly because of the surgical technique that positioned the
stomach conduit through the substernal route. Accordingly,
the stomach remained outside of the RT field. 
Several limitations stemmed from the retrospective nature
of this study. Adjuvant treatment selection was nonrandom-
ized, and there were significant differences in the patient
characteristics among the study groups. An attempt was
made to adjust for these imbalances in characteristics thro-
ugh multivariate analysis. In addition, data on the complica-
tions or patients’ quality of life, which are also important
endpoints, were not collected prospectively. Finally, the 
patient number in each treatment group was relatively small,
and the statistical power was low. 
Conclusion
CRT and AC might be considered relevant options for 
adjuvant treatment in patients with a resected ESCC. Assum-
ing that the patient can tolerate both chemotherapy and RT,
CRT may be an optimal choice because it could spare the 
patients from later high-dose irradiation for LRR without
causing an increase in the long-term postsurgical complica-
tions. On the other hand, this study cannot draw conclusions
regarding the most beneficial adjuvant treatment because of
the nonrandomized study design and the afore-mentioned
limitations. Additional well-designed prospective random-
ized trials will be needed to confirm these results. 
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